MCID: CHR070
MIFTS: 42

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Categories: Neuronal diseases

Aliases & Classifications for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MalaCards integrated aliases for Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

Name: Chronic Inflammatory Demyelinating Polyradiculoneuropathy 12 38 15 17
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 74
Polyradiculoneuropathy Chronic Inflammatory Demyelinating 56

Classifications:



External Ids:

Disease Ontology 12 DOID:5213
KEGG 38 H01527
ICD9CM 36 357.81
MeSH 45 D020277
NCIt 51 C84636
ICD10 34 G61.81
UMLS 74 C0393819

Summaries for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MalaCards based summary : Chronic Inflammatory Demyelinating Polyradiculoneuropathy, also known as polyradiculoneuropathy, chronic inflammatory demyelinating, is related to neuropathy, hereditary, with liability to pressure palsies and neuritis. An important gene associated with Chronic Inflammatory Demyelinating Polyradiculoneuropathy is MPZ (Myelin Protein Zero), and among its related pathways/superpathways are Allograft rejection and Interferon gamma signaling. The drugs Immunoglobulins and Rho(D) Immune Globulin have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, t cells and skin, and related phenotype is homeostasis/metabolism.

Related Diseases for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
# Related Disease Score Top Affiliating Genes
1 neuropathy, hereditary, with liability to pressure palsies 30.6 MPZ PMP22
2 neuritis 30.6 IFNG MPZ PMP22
3 chronic graft versus host disease 30.5 ALB IFNG
4 optic neuritis 30.5 HLA-DRB1 MPZ
5 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.3 IFNG IL17A
6 guillain-barre syndrome 30.3 ALB MPZ PMP22
7 polyradiculoneuropathy 30.1 ALB HLA-DRB1 IFNG IL17A MPZ NFASC
8 systemic lupus erythematosus 29.4 ALB HLA-DRB1 IFNB1 IFNG IL17A
9 multiple sclerosis 29.2 HLA-DRB1 IFNB1 IFNG IL17A MPZ PRF1
10 chronic inflammatory demyelinating polyneuropathy 12.4
11 lewis-sumner syndrome 11.7
12 chronic inflammatory demyelinating polyneuritis 11.5
13 x-linked charcot-marie-tooth disease 11.4
14 neuropathy 10.6
15 multifocal motor neuropathy 10.4
16 lupus erythematosus 10.4
17 congenital hypomyelination neuropathy 10.4 MPZ PMP22
18 charcot-marie-tooth hereditary neuropathy 10.4 MPZ PMP22
19 foot drop 10.4 MPZ PMP22
20 roussy-levy hereditary areflexic dystasia 10.4 MPZ PMP22
21 charcot-marie-tooth disease, demyelinating, type 1f 10.4 MPZ PMP22
22 charcot-marie-tooth disease, axonal, type 2d 10.3 MPZ PMP22
23 charcot-marie-tooth disease, x-linked dominant, 1 10.3 MPZ PMP22
24 charcot-marie-tooth disease, demyelinating, type 1c 10.3 MPZ PMP22
25 charcot-marie-tooth disease, demyelinating, type 1b 10.3 MPZ PMP22
26 charcot-marie-tooth disease, axonal, type 2b 10.3 MPZ PMP22
27 motor peripheral neuropathy 10.3 MPZ PMP22
28 charcot-marie-tooth disease, demyelinating, type 1a 10.3 MPZ PMP22
29 diabetes mellitus 10.3
30 polyneuropathy 10.3
31 charcot-marie-tooth disease, demyelinating, type 1d 10.3 MPZ PMP22
32 berylliosis 10.3 HLA-DRB1 IFNG
33 chronic beryllium disease 10.3 HLA-DRB1 IFNG
34 eosinophilia-myalgia syndrome 10.3 HLA-DRB1 IFNG
35 pelizaeus-merzbacher disease 10.3 MPZ PMP22
36 acute disseminated encephalomyelitis 10.3 HLA-DRB1 MPZ
37 microscopic colitis 10.3 HLA-DRB1 IFNG
38 charcot-marie-tooth disease and deafness 10.3 MPZ PMP22
39 idiopathic bronchiectasis 10.3 HLA-DRB1 IFNG
40 histoplasmosis 10.3 HLA-DRB1 IFNG
41 peanut allergy 10.3 HLA-DRB1 IFNG
42 myasthenia gravis 10.2
43 membranous nephropathy 10.2
44 glomerulonephritis 10.2
45 ptosis 10.2
46 myasthenia gravis congenital 10.2
47 tremor 10.2
48 tuberculous peritonitis 10.2 ALB IFNG
49 fascioliasis 10.2 ALB IFNG
50 anteroseptal myocardial infarction 10.2 ALB HLA-DRB1

Graphical network of the top 20 diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:



Diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Symptoms & Phenotypes for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MGI Mouse Phenotypes related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.23 ALB IFNB1 IFNG IL17A MPZ NFASC

Drugs & Therapeutics for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Drugs for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
2 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Not Applicable
3 gamma-Globulins Phase 4,Phase 3,Phase 2,Not Applicable
4 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Not Applicable
5 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Immunoglobulin G Phase 4,Phase 3,Phase 2,Not Applicable
8 Antineoplastic Agents, Immunological Phase 4,Phase 2,Phase 1
9
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
10
tannic acid Approved Phase 3 1401-55-4
11
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
12
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
13 Fingolimod Hydrochloride Phase 3
14 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
15 Antineoplastic Agents, Hormonal Phase 3,Phase 1,Phase 2
16 Hormone Antagonists Phase 3,Phase 1,Phase 2
17 glucocorticoids Phase 3,Phase 1,Phase 2
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2
19 Anti-Inflammatory Agents Phase 3,Phase 1,Phase 2
20 Hormones Phase 3,Phase 1,Phase 2
21 Pharmaceutical Solutions Phase 3,Phase 2
22
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
23
rituximab Approved Phase 2,Phase 1 174722-31-7 10201696
24
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2 6055-19-2, 50-18-0 2907
25
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
26
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
27
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
28
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
29
Mesna Approved, Investigational Phase 1, Phase 2 3375-50-6 598
30
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
31
Sargramostim Approved, Investigational Phase 1, Phase 2 123774-72-1, 83869-56-1
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
33
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
34 interferons Phase 2
35 Antiviral Agents Phase 2
36 Interferon-beta Phase 2
37 Adjuvants, Immunologic Phase 2,Phase 1
38 Anti-Infective Agents Phase 2
39 Micronutrients Phase 2
40 Vitamin B9 Phase 2
41 Folate Phase 2
42 Protective Agents Phase 2,Phase 1
43 Thioctic Acid Phase 2
44 Antioxidants Phase 2
45 Alpha-lipoic Acid Phase 2
46 Nutrients Phase 2
47 Vitamin B Complex Phase 2
48 Trace Elements Phase 2
49 Vitamins Phase 2
50 Antirheumatic Agents Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 55)
# Name Status NCT ID Phase Drugs
1 IVIg for Demyelination in Diabetes Mellitus Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Completed NCT03226119 Phase 4
3 Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Not yet recruiting NCT03684018 Phase 4
4 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
5 Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Completed NCT01625182 Phase 3 Fingolimod;Placebo Comparator
6 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
7 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
8 Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Completed NCT02293460 Phase 3 I10E
9 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
10 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
11 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
12 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
13 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
14 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
15 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
16 Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP Recruiting NCT02955355 Phase 3
17 Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP Recruiting NCT02549170 Phase 3
18 Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy Recruiting NCT02638207 Phase 3 NewGam
19 Panzyga in CIDP Administered at Different Infusion Rates Not yet recruiting NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
20 Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Terminated NCT02317562 Phase 3 I10E
21 Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Terminated NCT01225276 Phase 2, Phase 3 NewGam 10%;Placebo;NewGam 10%;NewGam 10%
22 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Unknown status NCT02967679 Phase 1, Phase 2 MD1003
23 Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
24 Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2 Subcutaneous immunoglobulin
25 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00962429 Phase 2 lipoic acid
26 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
27 The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies Recruiting NCT03864185 Phase 2
28 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Active, not recruiting NCT00278629 Phase 2
29 Stem Cell Transplantation for Stiff Person Syndrome (SPS) Active, not recruiting NCT02282514 Phase 1, Phase 2 Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF;Rituxan
30 A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Not yet recruiting NCT03861481 Phase 2 Rozanolixizumab
31 High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
32 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
33 A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 Recruiting NCT03275740 Phase 1 PF-06755347;Placebo comparator
34 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT01379833
35 sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN Unknown status NCT02271724
36 Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy (PIDC) Completed NCT03460951
37 MRI in Diagnosing and Monitoring CIDP Completed NCT02017769
38 Study of CIDP Patients During IVIG Treatment Completed NCT00305266 intravenous gammaglobulin
39 Effect of Resistance and Aerobic Exercise in CIDP or MMN Completed NCT02121678 Not Applicable
40 Immunoglobulin Dosage and Administration Form in CIDP and MMN Completed NCT02111590 Immunoglobulins
41 Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom Completed NCT01953822
42 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
43 Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035) Completed NCT00705614
44 Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Recruiting NCT02629796
45 Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP Recruiting NCT03779828
46 Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology Recruiting NCT03373370
47 Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial Recruiting NCT03584022 Not Applicable
48 Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases Recruiting NCT03656640 Gammanorm
49 Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and Neuropathy With Antibody A MAG Recruiting NCT03008733 Not Applicable
50 IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements Active, not recruiting NCT02414490 Intravenous Immunoglobulin

Search NIH Clinical Center for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Anatomical Context for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MalaCards organs/tissues related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

42
Spinal Cord, T Cells, Skin, Brain, Tongue, Kidney, Liver

Publications for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Articles related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

(show top 50) (show all 348)
# Title Authors Year
1
Simultaneous MR neurography and apparent T2 mapping in brachial plexus: Evaluation of patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 30266626 )
2019
2
Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. ( 30669140 )
2019
3
Absence of pathogenic mutations in CD59 in chronic inflammatory demyelinating polyradiculoneuropathy. ( 30794663 )
2019
4
Polyneuropathies and chronic inflammatory demyelinating polyradiculoneuropathy in multiple sclerosis. ( 30870805 )
2019
5
Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin. ( 29554579 )
2018
6
IgPro20, the Polyneuropathy and Treatment with Hizentra<sup>Ar</sup> study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG. ( 29764262 )
2018
7
Parallel fluctuation of anti-neurofascin 155 antibody levels with clinico-electrophysiological findings in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29249367 )
2018
8
Pyrexia-associated Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Case Report. ( 29709940 )
2018
9
A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol. ( 29603842 )
2018
10
Neuromuscular disease-specific questionnaire to assess quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29360221 )
2018
11
Risk factors for osteoporosis in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29896772 )
2018
12
Nerve Ultrasound Predicts Treatment Response in Chronic Inflammatory Demyelinating Polyradiculoneuropathy-a Prospective Follow-Up. ( 29435815 )
2018
13
History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 29866282 )
2018
14
Diagnosing chronic inflammatory demyelinating polyradiculoneuropathy with triple stimulation technique. ( 29926221 )
2018
15
A significant correlation between cauda equina conduction time and cerebrospinal fluid protein in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29249382 )
2018
16
Employment status of patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29999199 )
2018
17
Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. ( 30001923 )
2018
18
Clinical spectrum, treatment and outcome of children with suspected diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy. ( 30072201 )
2018
19
Lumbar plexus in patients with chronic inflammatory demyelinating polyradiculoneuropathy: evaluation with simultaneous T2 mapping and neurography method with SHINKEI. ( 30160180 )
2018
20
Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases. ( 30203907 )
2018
21
Chronic inflammatory demyelinating polyradiculoneuropathy: A case report. ( 30313036 )
2018
22
Remarkable Rituximab Response on Tremor Related to Acute-Onset Chronic Inflammatory Demyelinating Polyradiculoneuropathy in an Antineurofascin155 Immunoglobulin G4-Seropositive Patient. ( 30637275 )
2018
23
Chronic inflammatory demyelinating polyradiculoneuropathy and anesthesia: a case series. ( 28936613 )
2017
24
Chronic inflammatory demyelinating polyradiculoneuropathy-causing myelopathy. ( 28786217 )
2017
25
Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15. ( 29145880 )
2017
26
Blink R1 latency utility in diagnosis and treatment assessment of polyradiculoneuropathy-organomegaly-endocrinopathy-monoclonal protein-skin changes and chronic inflammatory demyelinating polyradiculoneuropathy. ( 28646568 )
2017
27
Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases. ( 28337614 )
2017
28
Multiple Sites Ultrasonography of Peripheral Nerves in Differentiating Charcot-Marie-Tooth Type 1A from Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 28522988 )
2017
29
Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. ( 28084646 )
2017
30
Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29089585 )
2017
31
Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. ( 28481421 )
2017
32
Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. ( 29185258 )
2017
33
Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study). ( 29119642 )
2017
34
Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment. ( 28382108 )
2017
35
ARTHUR ASBURY LECTURE: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of auto-immunity to nodal components. ( 29065233 )
2017
36
Fibronectin connecting segment-1 peptide inhibits pathogenic leukocyte trafficking and inflammatory demyelination in experimental models of chronic inflammatory demyelinating polyradiculoneuropathy. ( 28215575 )
2017
37
Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29092099 )
2017
38
Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29086018 )
2017
39
Clinical Characteristics and Treatment Response of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 29911781 )
2017
40
Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. ( 27781132 )
2016
41
Multiple Myeloma Associated Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Importance of Continued Surveillance. ( 28070468 )
2016
42
Stance Postural Strategies in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 26977594 )
2016
43
Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop. ( 27241239 )
2016
44
Intravenous Immunoglobulins Lower Inflammatory Gene Expression in Skin Biopsies of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. ( 27286956 )
2016
45
Chronic inflammatory demyelinating polyradiculoneuropathy occurring after autologous haematopoietic stem cell transplantation for multiple sclerosis. ( 28607734 )
2016
46
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Clinical Features, Diagnosis, and Current Treatment Strategies. ( 27902997 )
2016
47
A Bodybuilder With Weak Hands and Feet: Corticosteroid-Responsive Pure Motor Chronic Inflammatory Demyelinating Polyradiculoneuropathy Following Anabolic Steroid Use. ( 27438336 )
2016
48
Fatigue, Pain, Anxiety and Depression in Guillain-BarrAc Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 27077919 )
2016
49
Peripheral Nerve Ultrasonography in Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Multifocal Motor Neuropathy: Correlations with Clinical and Neurophysiological Data. ( 27313890 )
2016
50
Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-BarrAc syndrome: a case report. ( 27380808 )
2016

Variations for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Expression for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Search GEO for disease gene expression data for Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Pathways for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

GO Terms for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Cellular components related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 8.8 ALB MPZ NFASC

Biological processes related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 defense response to virus GO:0051607 9.54 IFNB1 IFNG PRF1
2 cell death GO:0008219 9.43 IL17A PMP22
3 peripheral nervous system development GO:0007422 9.4 NFASC PMP22
4 positive regulation of osteoclast differentiation GO:0045672 9.32 IFNG IL17A
5 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.26 IFNB1 IFNG
6 positive regulation of interleukin-23 production GO:0032747 9.16 IFNG IL17A
7 positive regulation of killing of cells of other organism GO:0051712 8.96 IFNG PRF1
8 myelination GO:0042552 8.8 MPZ NFASC PMP22

Molecular functions related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.8 IFNB1 IFNG IL17A

Sources for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....